萊美藥業：擬處置5家子公司資產
格隆匯2月11日丨萊美藥業(300006.SZ)公佈，公司自上市以來相繼收購或設立了與醫藥大健康領域相關的標的和子公司，實施醫藥行業內多元化戰略。但近年來醫藥行業發生了深刻變化，醫療行業大醫保時代來臨，如“4+7”帶量採購、按病種付費、限制輔助用藥等各項行業政策頻出，醫藥行業競爭加劇，公司針對實際市場情況對原定戰略做出了相應調整，提出了聚焦現有優勢細分領域，進一步做精做強的戰略思路。
此外，考慮到公司實際控制人邱宇與廣西梧州中恆集團股份有限公司(以下簡稱“中恆集團”)於近期簽署了《表決權委託協議》，協議生效後，中恆集團將成為公司單一擁有表決權份額最大的股東，公司實際控制人將變更為廣西壯族自治區人民政府國有資產監督管理委員會。鑑於中恆集團核心業務為中成藥製造，為避免中恆集團與公司及下屬子公司產生同業競爭，集中核心資源圍繞公司戰略發展規劃，以抗腫瘤、消化道、抗感染等優勢細分領域為基礎，打造甲狀腺疾病領域頭部企業，公司擬對可能產生同業競爭問題以及不符合未來戰略規劃的子公司股權進行處置。
本次公司擬處置資產包括：公司直接持有的湖南康源製藥有限公司(以下簡稱“湖南康源”)100%股權、公司直接持有的成都金星健康藥業有限公司(以下簡稱“成都金星”)90%股權、公司直接持有的四川禾正製藥有限責任公司(以下簡稱“四川禾正”)100%股權(含其全資子公司成都禾正生物科技有限公司(以下簡稱“成都禾正”)、四川萊禾醫藥科技有限公司(以下簡稱“萊禾科技”))、公司通過全資子公司重慶市萊美醫藥有限公司(以下簡稱“萊美醫藥”)間接持有的重慶萊美健康產業有限公司(以下簡稱“萊美健康”)60%股權和公司通過萊美醫藥間接持有的重慶萊美金鼠中藥飲片有限公司(以下簡稱“萊美金鼠”)70%股權。
本次公司擬採用整體在重慶產權聯合交易所公開掛牌轉讓的方式或以公開掛牌轉讓和引入戰略投資者相結合方式對相關資產進行處置，最終交易價格和交易對手尚無法確定，無法判斷是否構成關聯交易。公司已聘請具備證券期貨資質的審計機構、評估機構出具了審計報告和評估報告。本次交易標的股權轉讓能否成功實施尚存在不確定性，交易完成後，公司將不再持有前述交易標的股權，交易標的公司不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
